Investing.com — Dyne Therapeutics, a biotechnology firm, noticed its shares rise by as much as 10% after the market closed on Wednesday.
The surge in inventory value got here as the corporate introduced an investor convention name to overview new medical information.
The info is from its ACHIEVE trial, a examine specializing in a but undisclosed remedy. The corporate has not supplied additional particulars on the character of the trial or the info to be reviewed.
Dyne Therapeutics, which makes a speciality of creating therapies for sufferers with critical muscle illnesses, mentioned the overview of the info is scheduled for January 10.
This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.
By Michael S. Derby NEW YORK (Reuters) - Rate of interest cuts stay attainable in…
(Bloomberg) -- Mexico central financial institution members see odds of a weaker financial system this…
(Bloomberg) -- Concern engulfed Wall Avenue once more as US-China commerce tensions escalate, sparking a…
By Howard Schneider and Ann Saphir WASHINGTON (Reuters) - President Donald Trump's pause on a…
(Reuters) - Philadelphia Federal Reserve President Patrick Harker didn't touch upon the outlook for the…
(Reuters) - Philadelphia Federal Reserve President Patrick Harker didn't touch upon the outlook for the…